Pharmacological therapy for Gestational Diabetes Mellitus: A comprehensive overview

Q2 Medicine
Tanu Gautam , Amreen Shamsad , Renu Singh , S. Shabihe Raza Baqri , Monisha Banerjee
{"title":"Pharmacological therapy for Gestational Diabetes Mellitus: A comprehensive overview","authors":"Tanu Gautam ,&nbsp;Amreen Shamsad ,&nbsp;Renu Singh ,&nbsp;S. Shabihe Raza Baqri ,&nbsp;Monisha Banerjee","doi":"10.1016/j.obmed.2025.100587","DOIUrl":null,"url":null,"abstract":"<div><div>Gestational diabetes mellitus (GDM) is a prevalent metabolic condition affecting pregnant women, impairing glucose tolerance, and causing short- and long-term effects on mother, fetus, and neonate. The goal of management therapy during pregnancy is to obtain optimal glycemic control by preventing hyperglycemia and maintaining safety. The increasing prevalence of GDM worldwide is a rising concern, underscoring the need for dietary adjustments and improved detection, diagnostic and treatment strategies to overcome adverse consequences. International guidelines recommend pharmaceutical interventions for GDM when lifestyle adjustments do not attain glycemic control. Insulin is first-line treatment, but oral anti-hyperglycemic medications serve as often-used alternatives. Metformin and glyburide effectively regulate increased blood glucose in pregnancy. Metformin is preferred due to its ease of administration, reduced risk of hypoglycemia, and potential for improved long-term outcomes. Whereas glyburide is administered cautiously due to potential feto-maternal risk. In this review, the pharmaceutical alternatives for GDM have been discussed in detail, along with pharmacology and pharmacokinetics. The effects of metabolic and glycemic control on feto-maternal morbidity have also been elaborated, along with efficacy as well as side effects and long-term outcomes. However, their long-term safety profiles and fetal exposure remain unclear. By focusing on this research gap, we can explore effective management therapy by evaluating feto-maternal long-term outcomes through follow-up studies, comparing efficacy of pharmacological interventions, pharmacogenomics, digital health technologies, emerging pharmaceutical alternatives (GLP-1-Ra &amp; SGLT-2 inhibitors), and personalized medicine. By incorporating these advancements into clinical practice by healthcare professionals, the risk of adverse effects may decrease to improve health and well-being.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100587"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2451847625000077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Gestational diabetes mellitus (GDM) is a prevalent metabolic condition affecting pregnant women, impairing glucose tolerance, and causing short- and long-term effects on mother, fetus, and neonate. The goal of management therapy during pregnancy is to obtain optimal glycemic control by preventing hyperglycemia and maintaining safety. The increasing prevalence of GDM worldwide is a rising concern, underscoring the need for dietary adjustments and improved detection, diagnostic and treatment strategies to overcome adverse consequences. International guidelines recommend pharmaceutical interventions for GDM when lifestyle adjustments do not attain glycemic control. Insulin is first-line treatment, but oral anti-hyperglycemic medications serve as often-used alternatives. Metformin and glyburide effectively regulate increased blood glucose in pregnancy. Metformin is preferred due to its ease of administration, reduced risk of hypoglycemia, and potential for improved long-term outcomes. Whereas glyburide is administered cautiously due to potential feto-maternal risk. In this review, the pharmaceutical alternatives for GDM have been discussed in detail, along with pharmacology and pharmacokinetics. The effects of metabolic and glycemic control on feto-maternal morbidity have also been elaborated, along with efficacy as well as side effects and long-term outcomes. However, their long-term safety profiles and fetal exposure remain unclear. By focusing on this research gap, we can explore effective management therapy by evaluating feto-maternal long-term outcomes through follow-up studies, comparing efficacy of pharmacological interventions, pharmacogenomics, digital health technologies, emerging pharmaceutical alternatives (GLP-1-Ra & SGLT-2 inhibitors), and personalized medicine. By incorporating these advancements into clinical practice by healthcare professionals, the risk of adverse effects may decrease to improve health and well-being.

Abstract Image

妊娠期糖尿病的药物治疗:一个全面的概述
妊娠期糖尿病(GDM)是一种影响孕妇的普遍代谢疾病,损害糖耐量,并对母亲、胎儿和新生儿造成短期和长期影响。妊娠期管理治疗的目标是通过预防高血糖和维持安全来获得最佳的血糖控制。全球范围内GDM患病率的上升日益引起关注,强调需要调整饮食并改进检测、诊断和治疗策略,以克服不良后果。当生活方式调整不能达到血糖控制时,国际指南建议对GDM进行药物干预。胰岛素是一线治疗,但口服抗高血糖药物是常用的替代方案。二甲双胍和格列本脲可有效调节妊娠期血糖升高。二甲双胍是首选,因为它易于给药,降低低血糖的风险,并有改善长期预后的潜力。然而格列本脲的使用要谨慎,因为有潜在的胎母风险。在这篇综述中,详细讨论了GDM的药物替代品,以及药理学和药代动力学。代谢和血糖控制对母婴发病率的影响,以及疗效、副作用和长期结果也得到了详细阐述。然而,它们的长期安全性和胎儿暴露情况仍不清楚。通过关注这一研究空白,我们可以通过随访研究,比较药物干预、药物基因组学、数字健康技术、新兴药物替代品(GLP-1-Ra &;SGLT-2抑制剂)和个性化医疗。通过将这些进步纳入医疗保健专业人员的临床实践,不良反应的风险可能会降低,从而改善健康和福祉。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Obesity Medicine
Obesity Medicine Medicine-Public Health, Environmental and Occupational Health
CiteScore
5.50
自引率
0.00%
发文量
74
审稿时长
40 days
期刊介绍: The official journal of the Shanghai Diabetes Institute Obesity is a disease of increasing global prevalence with serious effects on both the individual and society. Obesity Medicine focusses on health and disease, relating to the very broad spectrum of research in and impacting on humans. It is an interdisciplinary journal that addresses mechanisms of disease, epidemiology and co-morbidities. Obesity Medicine encompasses medical, societal, socioeconomic as well as preventive aspects of obesity and is aimed at researchers, practitioners and educators alike.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信